6483-96-1 Usage
Uses
Used in Pharmaceutical Industry:
4,6-diphenyl-pyrimidine-2-carboxylic acid is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Chemical Research:
4,6-diphenyl-pyrimidine-2-carboxylic acid serves as a valuable research tool in the field of organic chemistry. It is used to study the properties and reactions of pyrimidine derivatives, contributing to the understanding of their chemical behavior and potential applications.
Used in Material Science:
4,6-diphenyl-pyrimidine-2-carboxylic acid is used as a building block in the development of new materials with specific properties. Its incorporation into polymers or other compounds can lead to materials with tailored characteristics for various applications, such as electronics or coatings.
Used in Industrial Applications:
4,6-diphenyl-pyrimidine-2-carboxylic acid is used as a raw material in the production of certain industrial chemicals. Its acidic properties make it suitable for use in processes that require acidic catalysts or reactants, contributing to the synthesis of a wide range of products.
Check Digit Verification of cas no
The CAS Registry Mumber 6483-96-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,4,8 and 3 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 6483-96:
(6*6)+(5*4)+(4*8)+(3*3)+(2*9)+(1*6)=121
121 % 10 = 1
So 6483-96-1 is a valid CAS Registry Number.
6483-96-1Relevant academic research and scientific papers
Discovery and mechanism of action studies of 4,6-diphenylpyrimidine-2-carbohydrazides as utrophin modulators for the treatment of Duchenne muscular dystrophy
Vuorinen, Aini,Wilkinson, Isabel V.L.,Chatzopoulou, Maria,Edwards, Ben,Squire, Sarah E.,Fairclough, Rebecca J.,Bazan, Noelia Araujo,Milner, Josh A.,Conole, Daniel,Donald, James R.,Shah, Nandini,Willis, Nicky J.,Martínez, R. Fernando,Wilson, Francis X.,Wynne, Graham M.,Davies, Stephen G.,Davies, Kay E.,Russell, Angela J.
supporting information, (2021/05/03)
Duchenne muscular dystrophy is a fatal disease with no cure, caused by lack of the cytoskeletal protein dystrophin. Upregulation of utrophin, a dystrophin paralogue, offers a potential therapy independent of mutation type. The failure of first-in-class utrophin modulator ezutromid/SMT C1100 in Phase II clinical trials necessitates development of compounds with better efficacy, physicochemical and ADME properties and/or complementary mechanisms. We have discovered and performed a preliminary optimisation of a novel class of utrophin modulators using an improved phenotypic screen, where reporter expression is derived from the full genomic context of the utrophin promoter. We further demonstrate through target deconvolution studies, including expression analysis and chemical proteomics, that this compound series operates via a novel mechanism of action, distinct from that of ezutromid.
